Karyopharm SENTRY trial meets spleen endpoint, misses symptom; DLBCL withdrawal agreed

Karyopharm Therapeutics Inc.

SENTRY trial: 50% SVR35 at wk24 vs 28% for ruxolitinib alone (p<0.0001); Abs-TSS comparable, not significant.
Promising OS signal: HR 0.43 (95% CI 0.19–1.00, nominal p=0.0222); continued follow-up planned.
FDA requested withdrawal of accelerated approval for XPOVIO in DLBCL; company agreed, ceases development.
Private placement with RA Capital: ~$30M gross (1.03M shares at $6.785, pre-funded warrants); warrants at $10.
ATM sales in March 2026 raised ~$9.6M net; capital raise trigger satisfied for credit agreement amendments.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Karyopharm Therapeutics Inc. entered into Securities Purchase Agreement with RA Capital Management valued at gross proceeds of approximately $30 million (effective 2026-03-24).

Action: entry
Agreement: equity purchase
Counterparty: RA Capital Management
Value: gross proceeds of approximately $30 million
Effective: 2026-03-24

Exact text from the filing

On March 24, 2026, Karyopharm Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with RA Capital Management (the “Investor”), pursuant to which the Company agreed to issue and sell (i) 1,030,354 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $6.785 per share and, in lieu of Common Stock, pre-funded warrants to purchase up to 3,391,164 shares of Common Stock (the “Pre-Funded Warrants”) at a purchase price of $6.7849 per pre-funded warrant, and (ii) accompanying warrants to purchase 4,421,518 shares of Common Stock with an exercise price of $10.00 per share (the “Common Stock Warrants”) to the Investor in a private placement (collectively, the “Private Placement”).

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-120770

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.